Abionic raises CHF 20 million in financing
28.03.2018
Great news for our Venture Kick 2010 alumnus. Abionic announced today closing a CHF 20 million series C financing round from renowned industry experts and business angels. A clinical study will start in April.
 |
 |
The EPFL spin-off develops rapid diagnostic solutions such as the abioSCOPE, a rapid diagnostic platform for clinical laboratories allowing healthcare professionals to make diagnoses from a single drop of a patient’s blood. Possible applications are numerous: rapid tests for allergies, iron deficiency diseases and sepsis. Following the successful round, the startup will use the proceeds to extend its portfolio of Point-of-Care IVD tests for critical care and emergency medicine. It will launch in April a multinational sepsis impact study of its Pancreatic Stone Protein (PSP) test, capable of showing an indication of sepsis within 5 minutes. The study will evaluate the efficacy of the new technology as a sepsis diagnosis and management tool for clinicians among 300 patients in 14 ICU cities in Switzerland, Italy, France and the UK.
Founded in 2010, Abionic developed its nanotechnology within the EPFL and is now based at the Biopôle in Lausanne. Recently, it obtained registration of its first rapid allergy tests in the United States by the Food and Drug Administration (FDA). The company is continuously developing additional rapid tests, e.g. for allergy, asthma and thrombosis. Dr. Nicolas Durand, CEO of Abionic explained "With Venture Kick, the company obtained precious early stage funding allowing us to demonstrate the potential of our technology."
The round was led by Pierangelo Bottinelli, Chairman of Symphony International Holdings Limited, and included Philippe Glatz (Chairman of two private hospitals), Peter Brabeck-Letmathe (former CEO and Chairman of Nestlé), Arkady Volozh (Co-Founder and CEO of Yandex), Jean-Bernard and Nelson Dumas (Owners of Dumas Construction), Investiere AG and Zürcher Kantonalbank.
Source: Abionic Press Release
Founded in 2010, Abionic developed its nanotechnology within the EPFL and is now based at the Biopôle in Lausanne. Recently, it obtained registration of its first rapid allergy tests in the United States by the Food and Drug Administration (FDA). The company is continuously developing additional rapid tests, e.g. for allergy, asthma and thrombosis. Dr. Nicolas Durand, CEO of Abionic explained "With Venture Kick, the company obtained precious early stage funding allowing us to demonstrate the potential of our technology."
The round was led by Pierangelo Bottinelli, Chairman of Symphony International Holdings Limited, and included Philippe Glatz (Chairman of two private hospitals), Peter Brabeck-Letmathe (former CEO and Chairman of Nestlé), Arkady Volozh (Co-Founder and CEO of Yandex), Jean-Bernard and Nelson Dumas (Owners of Dumas Construction), Investiere AG and Zürcher Kantonalbank.
Source: Abionic Press Release